NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 48 filers reported holding NEUBASE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $28 | -22.2% | 150 | -19.8% | 0.00% | – |
| Q4 2022 | $36 | – | 187 | +24.7% | 0.00% | – |
| Q3 2022 | $0 | – | 150 | -35.1% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 231 | -77.6% | 0.00% | – |
| Q1 2022 | $2,000 | -92.3% | 1,029 | -89.1% | 0.00% | – |
| Q4 2021 | $26,000 | -88.1% | 9,417 | -84.4% | 0.00% | – |
| Q3 2021 | $218,000 | -62.0% | 60,230 | -49.7% | 0.00% | – |
| Q2 2021 | $574,000 | +218.9% | 119,678 | +393.9% | 0.00% | – |
| Q1 2021 | $180,000 | +11.8% | 24,231 | +5.8% | 0.00% | – |
| Q4 2020 | $161,000 | +80.9% | 22,905 | +96.2% | 0.00% | – |
| Q3 2020 | $89,000 | -32.6% | 11,672 | -22.3% | 0.00% | – |
| Q2 2020 | $132,000 | +94.1% | 15,030 | +57.6% | 0.00% | – |
| Q1 2020 | $68,000 | +21.4% | 9,537 | +22.3% | 0.00% | – |
| Q4 2019 | $56,000 | +51.4% | 7,800 | +4.1% | 0.00% | – |
| Q3 2019 | $37,000 | – | 7,490 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greenlight Capital | 2,027,027 | $14,169,000 | 0.85% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 103,500 | $723,000 | 0.55% |
| Sio Capital Management, LLC | 293,699 | $2,053,000 | 0.42% |
| GSA CAPITAL PARTNERS LLP | 121,389 | $849,000 | 0.14% |
| Frontier Wealth Management LLC | 145,000 | $1,014,000 | 0.08% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 311,000 | $2,174,000 | 0.06% |
| Oak Grove Capital LLC | 19,175 | $134,000 | 0.04% |
| PREMIER ASSET MANAGEMENT LLC | 14,977 | $105,000 | 0.02% |
| Trexquant Investment LP | 15,479 | $108,000 | 0.01% |
| PILLAR PACIFIC CAPITAL MANAGEMENT LLC | 19,800 | $138,000 | 0.01% |